吸入激素联合口服缓释茶碱控制中度持续哮喘的观察

发布时间：2018-02-27 02:13

本文关键词： 哮喘多索茶碱布地奈德　出处：《实用医学杂志》2014年24期 　论文类型：期刊论文

【摘要】：目的:观察吸入激素联合缓释茶碱对中度持续哮喘患者的治疗作用。方法:中度哮喘患者60例,随机分为试验组30例和对照组30例。试验组患者每日吸入普米克都保,每吸200μg,每日2次;口服多索茶碱片0.2每日2次。对照组患者每日吸入布地奈德/福莫特罗每吸160/4.5μg,每日2吸。疗程3个月。比较治疗前后Fe NO、痰嗜酸粒细胞计数、PEF、ACT评分等指标的变化,并与对照组相比较,评估该方案的临床使用价值。结果:治疗1个月时,试验组在改善PEF、ACT评分方面,明显不及对照组(均P0.05),痰嗜酸粒细胞比例的改善优于对照组(P0.05),Fe NO无明显区别(P0.05);治疗3个月时,试验组对痰嗜酸粒细胞比例的改善优于对照组(P0.05),对Fe NO、PEF、ACT评分的改善与对照组无明显区别(均P0.05)。结论:布地奈德/多索茶碱与布地奈德/福莫特罗控制哮喘的效果无明显区别。
[Abstract]:Objective: to observe the therapeutic effect of inhaled hormone combined with sustained-release theophylline on patients with moderate persistent asthma. Methods: 60 patients with moderate asthma were randomly divided into experimental group (n = 30) and control group (n = 30). Inhaled 200 渭 g, twice a day; Oral doxofylline tablets were taken orally twice a day. In control group, budesonide / formoterol was inhaled at 1604.5 渭 g / d, twice a day for 3 months. The changes of Fe no, sputum eosinophil count and PEFN ACT score were compared before and after treatment. Compared with the control group, the clinical value of the regimen was evaluated. Results: after one month of treatment, the trial group improved the score of PEFN ACT. The percentage of eosinophil in sputum was significantly better than that in the control group (P 0.05), and there was no significant difference between control group (P 0.05) and control group (P 0.05), and after 3 months of treatment, the ratio of eosinophil in sputum was improved. The percentage of eosinophils in sputum in the experimental group was better than that in the control group (P0.05A), and the improvement of the score of FeNO-PEFFCT-ACT was not significantly different from that of the control group (P 0.05). Conclusion: there is no significant difference in the effect of budesonide / doxofylline and budesonide / formoterol in the control of asthma.
【作者单位】：郑州大学第一附属医院呼吸与危重症医学科;郑州大学人民医院呼吸与危重症医学科;
【基金】：河南省医疗卫生专项基金(编号:1020124)
【分类号】：R562.25

【共引文献】